We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

170 hedge funds and large institutions have $1.98B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2019 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 60 increasing their positions, 34 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

364% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 11

130% more call options, than puts

Call options by funds: $57.2M | Put options by funds: $24.9M

76% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 34

39% more capital invested

Capital invested by funds: $1.42B → $1.98B (+$558M)

30% more funds holding

Funds holding: 131170 (+39)

9% more funds holding in top 10

Funds holding in top 10: 1112 (+1)

Holders
170
Holders Change
+39
Holders Change %
+29.77%
% of All Funds
3.68%
Holding in Top 10
12
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+9.09%
% of All Funds
0.26%
New
51
Increased
60
Reduced
34
Closed
11
Calls
$57.2M
Puts
$24.9M
Net Calls
+$32.4M
Net Calls Change
+$26M

BHVN Hedge Fund Activity: Q1 2019 in Review

170 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2019, worth a combined $1.98B — up 39% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new BHVN positions and 11 closed out — a net gain of 40 holders — while 60 added to existing stakes and 34 trimmed.

The largest buyer was Oracle Investment Management, adding an estimated $36.6M. The largest seller was Janus Henderson Group, cutting an estimated $81.7M.

  • 170 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2019, up from 131 in Q4 2018.
  • Funds reported $1.98B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2019, up 39% quarter-over-quarter.
  • 51 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2019 and 11 closed out, a net change of +40 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2019 was Oracle Investment Management, an estimated $36.6M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2019 was Janus Henderson Group, an estimated $81.7M sold.

Based on aggregated 13F filings for Q1 2019.